Developer docs
API playgroundTry for free, no card

Search company profiles

Aarvik Therapeutics

Full company profile

uuid00007pj

Namestring
Aarvik Therapeutics
Legal namestring
Aarvik Therapeutics, Inc.
Websiteurl
aarviktx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Aarvik Therapeutics, Inc. is a private, Hayward, California-based biotechnology company (founded 2020/launched June 2021, 11–50 employees) developing precision antibody-drug conjugates (ADCs) for oncology. Its scientific foundation rests on two proprietary platforms: MUTTA™ (Multi-epitope Targeting Tetravalent Antibody), which engineers site-specifically conjugated tetravalent antibodies capable of binding up to four epitopes on one or more tumor antigens to overcome antigen escape and unlock low-copy-number tumor targets; and AQUALINK™, which supplies hydrophilic beta-glucuronidase cleavable linkers paired with exatecan payloads for next-generation ADC chemistry. The lead clinical-stage asset is ARR-002 (AV-P138-ADC), a MUC16/NaPi2b dual-target tetravalent ADC for ovarian and endometrial cancers that received FDA IND clearance in May 2026, with Phase 1 dosing expected in H2 2026.

The company operates a partner-led, platform-out-licensing business model: it conducts discovery and preclinical development internally and licenses candidates to pharmaceutical partners who fund and execute clinical development and commercialization. The flagship relationship is with ArriVent BioPharma, which entered a research collaboration in December 2021 (potential value ~$100M in milestones plus royalties) and exercised an exclusive license to ARR-002 in August 2024. Aarvik is pre-revenue, generating income solely from upfront payments, research funding, opt-in payments, and contingent milestones/royalties. Capital sources include a Series Seed round (August 2021), an interim financing (December 2024), and a Series Seed 2 round (September 2025) that included a $2M strategic investment from India-based Laurus Labs. Scientific leadership is anchored by Genentech alumni, including ADC pioneer Jagath Reddy Junutula (co-inventor of THIOMAB technology, contributor to Kadcyla and Polivy) and protein engineer Sachdev Sidhu, supported by a board and SAB that includes former Genentech EVP Richard Scheller.

Short descriptiontext

Aarvik Therapeutics is a private Hayward, California-based biotech developing precision antibody-drug conjugates (ADCs) for oncology using its proprietary MUTTA™ tetravalent antibody and AQUALINK™ linker platforms, partnering with pharmaceutical companies (notably ArriVent BioPharma) for clinical development and commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHayward, United States
HQ citystring
Hayward
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, oncology therapeutics, tetravalent antibody platforms, ADC drug development, biotechnology licensing
Industry4 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antibody-Drug Conjugate Oncology Therapeutics
No data
Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Aarvik receives upfront payments, research funding, and opt-in payments from partners for discovery and preclinical development programs. The company is eligible to receive contingent development and commercial milestones. Revenue model is typical of early-stage biotech platforms - upfront payments fund operations while milestone payments and royalties provide upside upon clinical and commercial success.

aarviktx.com
2Royalties on Commercial Sales
TypeLicensing Royalties
Description

Aarvik receives royalties on net sales of successfully commercialized products developed through partnerships. For the ArriVent collaboration, the company is eligible for royalties in addition to upfront, research, and milestone payments.

aarviktx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1MUTTA™
Description

Multi-epitope Targeting Tetravalent Antibody platform for developing next-generation antibody-drug conjugates (ADCs) with improved therapeutic window.

aarviktx.com
+1 more record
Core offering1 text field

Aarvik Therapeutics is a clinical-stage biotechnology company that develops precision oncology therapeutics using proprietary antibody-drug conjugate (ADC) platforms. Its core offerings include the MUTTA™ (Multi-epitope Targeting Tetravalent Antibody) platform, which enables multi-targeting tetravalent antibody architectures, and the AQUALINK™ linker-payload platform. The company primarily monetizes these assets by discovering and conducting preclinical development of ADC candidates and then out-licensing them to pharmaceutical partners for clinical development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • FDA IND clearance achieved for ARR-002 (AV-P138-ADC) in May 2026 for ovarian and endometrial cancers, with Phase 1 clinical trial expected to initiate and first patient dosed in H2 2026.
Product overview1 text field

Aarvik Therapeutics is an ADC-focused biotechnology company developing a portfolio of proprietary technology platforms and ADC drug candidates for oncology. The company's core offerings include the MUTTA™ (MUlti-epitope Targeting Tetravalent Antibody) platform for multi-targeting ADC development and the AQUALINK™ platform for advanced linker-payload technology. The lead program AV-P138-ADC (ARR-002) is a dual-target ADC co-developed with ArriVent BioPharma for ovarian and endometrial cancers. The MUTTA platform enables combining multiple low copy number receptors through multi-valent architecture (up to 4 targets) with site-specific conjugation, improving therapeutic window by lowering minimum effective dose while maintaining or improving maximum tolerated dose.

Product and service1 record
1MUTTA™ ADC Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-15
Description

ArriVent exercised its option to exclusively license the collaboration program (AV-P138-ADC/ARR-002) discovered by Aarvik. Aarvik received upfront payment, research funding, and opt-in payment, and is eligible for contingent development and commercial milestones plus royalties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-21
Description

Strategic research collaboration to develop and commercialize a novel oncology-focused ADC candidate. Aarvik is responsible for discovery and preclinical development using its proprietary modular platform. ArriVent is responsible for clinical development and commercialization. Aarvik receives upfront payment, research funding, and is eligible for option fees, development and commercial milestones totaling approximately $100 million plus royalties.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC platform company developing novel antibody conjugates for oncology using proprietary linker-payload platforms (Dolasynthen, Immunosynthen). Closely comparable to Aarvik as a platform ADC biotech licensing assets to pharma partners, with multiple programs in the clinic.

TypeDirect peer
Description

Commercial-stage ADC company developing pyrrolobenzodiazepine-based antibody-drug conjugates for hematologic and solid tumors. Directly comparable as an ADC-specialist with platform technology, multiple pipeline assets, and pharma partnerships.

TypeBroad incumbent
Description

Pioneer in ADC field (Elahere, now under AbbVie) with a broad ADC platform targeting multiple oncology indications. Comparable to Aarvik as an ADC-focused oncology company, though materially larger and now part of a top-5 pharma group.

TypeBroad incumbent
Description

Global leader in ADC drug development (Enhertu, Datroway) with multiple partnered and wholly-owned ADC programs across oncology. Sets the competitive benchmark for ADC technology and partnership economics relevant to Aarvik's business model.

TypeDirect peer
Description

Clinical-stage ADC and antibody therapeutics company developing multi-modality oncology candidates. Directly comparable as a small-cap ADC platform pursuing differentiated targets, with an analogous discovery-to-clinic trajectory.

TypeDirect peer
Description

Clinical-stage ADC company developing next-generation antibody-drug conjugates for solid tumors, recently acquired by Genmab. Directly comparable as a privately funded, platform-driven ADC developer that scaled through partnership economics.

TypeEmerging player
Description

Privately held ADC platform company developing differentiated linker chemistries and conjugation approaches. Comparable to Aarvik in stage and platform-centric approach, with overlap in linker-payload innovation relevant to AQUALINK.

TypeDirect peer
Description

Clinical-stage oncology company developing immune-stimulating antibody-drug conjugates (ISACs). Comparable as a small-cap ADC platform with proprietary linker/chemistry technology and pharma partnership activity.

TypeEmerging player
Description

ADC platform company (acquired by Eli Lilly in 2024) developing next-generation antibody-drug conjugates with novel hydrophilic linkers. Closely comparable to Aarvik's AQUALINK concept and to its licensing-based growth model.

TypeEmerging player
Description

Preclinical/early-clinical ADC platform company developing linker chemistries for site-specific antibody-drug conjugates, acquired by AstraZeneca. Comparable to Aarvik as a linker-platform innovator whose exit validates pharma demand for differentiated ADC technology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aarvik Therapeutics

Antibody-Drug Conjugate Oncology Therapeuticsaarviktx.com

Aarvik Therapeutics is a private Hayward, California-based biotech developing precision antibody-drug conjugates (ADCs) for oncology using its proprietary MUTTA™ tetravalent antibody and AQUALINK™ linker platforms, partnering with pharmaceutical companies (notably ArriVent BioPharma) for clinical development and commercialization.

What Aarvik Therapeutics does

Aarvik Therapeutics, Inc. is a private, Hayward, California-based biotechnology company (founded 2020/launched June 2021, 11–50 employees) developing precision antibody-drug conjugates (ADCs) for oncology. Its scientific foundation rests on two proprietary platforms: MUTTA™ (Multi-epitope Targeting Tetravalent Antibody), which engineers site-specifically conjugated tetravalent antibodies capable of binding up to four epitopes on one or more tumor antigens to overcome antigen escape and unlock low-copy-number tumor targets; and AQUALINK™, which supplies hydrophilic beta-glucuronidase cleavable linkers paired with exatecan payloads for next-generation ADC chemistry. The lead clinical-stage asset is ARR-002 (AV-P138-ADC), a MUC16/NaPi2b dual-target tetravalent ADC for ovarian and endometrial cancers that received FDA IND clearance in May 2026, with Phase 1 dosing expected in H2 2026.

The company operates a partner-led, platform-out-licensing business model: it conducts discovery and preclinical development internally and licenses candidates to pharmaceutical partners who fund and execute clinical development and commercialization. The flagship relationship is with ArriVent BioPharma, which entered a research collaboration in December 2021 (potential value ~$100M in milestones plus royalties) and exercised an exclusive license to ARR-002 in August 2024. Aarvik is pre-revenue, generating income solely from upfront payments, research funding, opt-in payments, and contingent milestones/royalties. Capital sources include a Series Seed round (August 2021), an interim financing (December 2024), and a Series Seed 2 round (September 2025) that included a $2M strategic investment from India-based Laurus Labs. Scientific leadership is anchored by Genentech alumni, including ADC pioneer Jagath Reddy Junutula (co-inventor of THIOMAB technology, contributor to Kadcyla and Polivy) and protein engineer Sachdev Sidhu, supported by a board and SAB that includes former Genentech EVP Richard Scheller.

Aarvik Therapeutics firmographics

Firmographics
Name
Aarvik Therapeutics
Legal name
Aarvik Therapeutics, Inc.
Website
https://aarviktx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Aarvik Therapeutics is a private Hayward, California-based biotech developing precision antibody-drug conjugates (ADCs) for oncology using its proprietary MUTTA™ tetravalent antibody and AQUALINK™ linker platforms, partnering with pharmaceutical companies (notably ArriVent BioPharma) for clinical development and commercialization.
Ownership category
akta.pro rank

Aarvik Therapeutics industry classification

Industry
Product category
Antibody-Drug Conjugate Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody drug conjugates
  • Oncology therapeutics
  • Tetravalent antibody platforms
  • ADC drug development
  • Biotechnology licensing

Where Aarvik Therapeutics is headquartered

Location

Headquarters

HQ city
Hayward
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aarvik Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Milestone Payments: Aarvik receives upfront payments, research funding, and opt-in payments from partners for discovery and preclinical development programs. The company is eligible to receive contingent development and commercial milestones. Revenue model is typical of early-stage biotech platforms - upfront payments fund operations while milestone payments and royalties provide upside upon clinical and commercial success.
  2. Royalties on Commercial Sales: Aarvik receives royalties on net sales of successfully commercialized products developed through partnerships. For the ArriVent collaboration, the company is eligible for royalties in addition to upfront, research, and milestone payments.

Distribution channels1 record

Marketing channels4 records

Aarvik Therapeutics product offering

Product offering

Core offering

Aarvik Therapeutics is a clinical-stage biotechnology company that develops precision oncology therapeutics using proprietary antibody-drug conjugate (ADC) platforms. Its core offerings include the MUTTA™ (Multi-epitope Targeting Tetravalent Antibody) platform, which enables multi-targeting tetravalent antibody architectures, and the AQUALINK™ linker-payload platform. The company primarily monetizes these assets by discovering and conducting preclinical development of ADC candidates and then out-licensing them to pharmaceutical partners for clinical development and commercialization.

Product overview

Aarvik Therapeutics is an ADC-focused biotechnology company developing a portfolio of proprietary technology platforms and ADC drug candidates for oncology. The company's core offerings include the MUTTA™ (MUlti-epitope Targeting Tetravalent Antibody) platform for multi-targeting ADC development and the AQUALINK™ platform for advanced linker-payload technology. The lead program AV-P138-ADC (ARR-002) is a dual-target ADC co-developed with ArriVent BioPharma for ovarian and endometrial cancers. The MUTTA platform enables combining multiple low copy number receptors through multi-valent architecture (up to 4 targets) with site-specific conjugation, improving therapeutic window by lowering minimum effective dose while maintaining or improving maximum tolerated dose.

Differentiator

Problem solved

Functional benefit

Brands

  • MUTTA™: Multi-epitope Targeting Tetravalent Antibody platform for developing next-generation antibody-drug conjugates (ADCs) with improved therapeutic window.
  • AQUALINK™

Products and services

  • MUTTA™ ADC Platform

Quantifiable outcome

  • FDA IND clearance achieved for ARR-002 (AV-P138-ADC) in May 2026 for ovarian and endometrial cancers, with Phase 1 clinical trial expected to initiate and first patient dosed in H2 2026.

Companies that use Aarvik Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Aarvik Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aarvik Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • ArriVent BioPharmacoreOEM/ Whitelabel/ Licensing Partner · 15 August 2024ArriVent exercised its option to exclusively license the collaboration program (AV-P138-ADC/ARR-002) discovered by Aarvik. Aarvik received upfront payment, research funding, and opt-in payment, and is eligible for contingent development and commercial milestones plus royalties.
  • ArriVent BioPharmacoreStrategic or Co-development Partner · 21 December 2021Strategic research collaboration to develop and commercialize a novel oncology-focused ADC candidate. Aarvik is responsible for discovery and preclinical development using its proprietary modular platform. ArriVent is responsible for clinical development and commercialization. Aarvik receives upfront payment, research funding, and is eligible for option fees, development and commercial milestones totaling approximately $100 million plus royalties.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Aarvik Therapeutics competitors and assessment

Company assessment

Direct peers

  • Mersana Therapeutics: Clinical-stage ADC platform company developing novel antibody conjugates for oncology using proprietary linker-payload platforms (Dolasynthen, Immunosynthen). Closely comparable to Aarvik as a platform ADC biotech licensing assets to pharma partners, with multiple programs in the clinic.
  • ADC Therapeutics: Commercial-stage ADC company developing pyrrolobenzodiazepine-based antibody-drug conjugates for hematologic and solid tumors. Directly comparable as an ADC-specialist with platform technology, multiple pipeline assets, and pharma partnerships.
  • Pyxis Oncology: Clinical-stage ADC and antibody therapeutics company developing multi-modality oncology candidates. Directly comparable as a small-cap ADC platform pursuing differentiated targets, with an analogous discovery-to-clinic trajectory.
  • ProfoundBio: Clinical-stage ADC company developing next-generation antibody-drug conjugates for solid tumors, recently acquired by Genmab. Directly comparable as a privately funded, platform-driven ADC developer that scaled through partnership economics.
  • Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody-drug conjugates (ISACs). Comparable as a small-cap ADC platform with proprietary linker/chemistry technology and pharma partnership activity.

Broad incumbents

  • ImmunoGen (AbbVie): Pioneer in ADC field (Elahere, now under AbbVie) with a broad ADC platform targeting multiple oncology indications. Comparable to Aarvik as an ADC-focused oncology company, though materially larger and now part of a top-5 pharma group.
  • Daiichi Sankyo: Global leader in ADC drug development (Enhertu, Datroway) with multiple partnered and wholly-owned ADC programs across oncology. Sets the competitive benchmark for ADC technology and partnership economics relevant to Aarvik's business model.

Emerging players

  • Tubulis: Privately held ADC platform company developing differentiated linker chemistries and conjugation approaches. Comparable to Aarvik in stage and platform-centric approach, with overlap in linker-payload innovation relevant to AQUALINK.
  • Mablink Bioscience (Eli Lilly): ADC platform company (acquired by Eli Lilly in 2024) developing next-generation antibody-drug conjugates with novel hydrophilic linkers. Closely comparable to Aarvik's AQUALINK concept and to its licensing-based growth model.
  • Araris Biotech (AstraZeneca): Preclinical/early-clinical ADC platform company developing linker chemistries for site-specific antibody-drug conjugates, acquired by AstraZeneca. Comparable to Aarvik as a linker-platform innovator whose exit validates pharma demand for differentiated ADC technology.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Aarvik Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aarvik Therapeutics leadership team

Management profile

Number of profiles

Profiles20 records

Aarvik Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aarvik Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aarvik Therapeutics

What does Aarvik Therapeutics do?

Aarvik Therapeutics is a clinical-stage biotechnology company that develops precision oncology therapeutics using proprietary antibody-drug conjugate (ADC) platforms. Its core offerings include the MUTTA™ (Multi-epitope Targeting Tetravalent Antibody) platform, which enables multi-targeting tetravalent antibody architectures, and the AQUALINK™ linker-payload platform. The company primarily monetizes these assets by discovering and conducting preclinical development of ADC candidates and then out-licensing them to pharmaceutical partners for clinical development and commercialization.

Is Aarvik Therapeutics a public or private company?

Aarvik Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aarvik Therapeutics founded?

Aarvik Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Aarvik Therapeutics based?

Aarvik Therapeutics is headquartered in Hayward, United States, in the North America region.

How does Aarvik Therapeutics make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are royalties on Commercial Sales.

Who are Aarvik Therapeutics's main competitors?

Direct peers on record are Mersana Therapeutics, ADC Therapeutics, Pyxis Oncology, ProfoundBio and Bolt Biotherapeutics. Broad incumbents are ImmunoGen (AbbVie) and Daiichi Sankyo. Emerging players are Tubulis, Mablink Bioscience (Eli Lilly) and Araris Biotech (AstraZeneca).

Does Aarvik Therapeutics have an API?

No public API is recorded for Aarvik Therapeutics.

What industry is Aarvik Therapeutics in?

Aarvik Therapeutics's product category is Antibody-Drug Conjugate Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC ConferenceAarvik Therapeutics announced that its first MUTTA-based ADC, AV-P138-ADC, reached clinical stage with the first patient dosed in a Phase 1 trial. The company also signed a license agreement with Laurus Labs for two MUTTA ADCs in India, and presented platform data at the WADC conference.FinancialContent Business PageAarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC ConferenceAarvik Therapeutics announced that its first MUTTA-based ADC, AV-P138-ADC, reached clinical stage with first patient dosing in a US Phase 1 trial. The company also licensed two MUTTA ADCs to Laurus Labs for development in India, and presented platform data at the WADC conference.PharmiWeb.comAarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026Aarvik Therapeutics, an ADC-focused biotechnology company, will present two posters and a minisymposium talk at the AACR Annual Meeting 2026 in San Diego, California, showcasing data from its proprietary MUTTA™ and AQUALINK™ platforms for cancer therapy. The company will highlight AV-P138-ADC (ARR-002), a novel dual-target ADC developed in collaboration with ArriVent BioPharma for ovarian and endometrial cancers, along with validation data demonstrating improved therapeutic windows for multi-target ADCs compared to single-target approaches.Stock TitanAarvik Therapeutics shows MUTTA, AQUALINK ADCs at AACR 2026Aarvik Therapeutics announced it will present two posters and a minisymposium at the AACR Annual Meeting 2026 in San Diego, California, showcasing its proprietary MUTTA™ and AQUALINK™ ADC platforms for cancer therapy. The company, along with collaborator ArriVent BioPharma, will present data on AV-P138-ADC (ARR-002), a dual-target ADC for ovarian and endometrial cancers that Aarvik discovered and ArriVent exclusively licensed for global development. The presentations will demonstrate in vitro and in vivo validation of multi-target MUTTA™ ADCs with improved therapeutic windows compared to single-target ADCs, as well as novel linker-payloads from the AQUALINK™ platform with superior hydrophilic properties.VC News DailyAarvik Therapeutics Announces Successful Series Seed 2 Financing RoundAarvik Therapeutics announced it successfully closed a Series Seed 2 financing round. The biotechnology company specializes in engineering precision medicines for cancer therapy.FinSMEsAarvik Therapeutics Closes Series Seed 2 FundingAarvik Therapeutics, a Hayward, California-based biotechnology company focused on antibody drug conjugates (ADCs) for cancer therapy, closed a Series Seed 2 financing round with participation from existing investors and new investors including Laurus Labs. The company intends to use the proceeds to expand its operations and development efforts, building on its proprietary MUTTA™ platform designed to improve the therapeutic index of ADC-based oncology treatments. The funding round included pharma and tech professionals as well as contract research and manufacturing organizations.Business InsiderArriVent BioPharma’s Strategic Licensing and Partnerships Position It for Growth in ADC DevelopmentAnalysts Sam Slutsky and H.C. Wainwright reiterated Buy ratings on ArriVent BioPharma with price targets of $38 and $39, citing its licensing deal with Lepu Biopharma for ADC MRG007. The company plans its first IND application in the first half of 2025, and collaborations with Alphamab and Aarvik Therapeutics expand its pipeline.Business InsiderBuy Rating Affirmed on ArriVent BioPharma’s Strong Clinical Developments and Strategic PartnershipsAnalysts Sam Slutsky and Jefferies affirmed Buy ratings on ArriVent BioPharma with price targets of $33 and $35, citing firmonertinib's phase 3 trial and a September WCLC proof-of-concept presentation. The company's ADC partnership with Alphamab and Aarvik Therapeutics adds pipeline value.Business Wire BlogAarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharmaAarvik Therapeutics announced that ArriVent BioPharma exercised the option to exclusively license its collaboration program. The deal, entered into December 21, 2021, assigns ArriVent clinical development and commercialization, with Aarvik receiving upfront, research, and opt-in payments plus milestones and royalties.Business Wire BlogAarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody PlatformAarvik Therapeutics and ArriVent Biopharma announced a research collaboration to develop and commercialize an undisclosed oncology drug candidate. Aarvik will handle discovery and preclinical development, while ArriVent will manage clinical development and commercialization. The collaboration could be worth approximately $100 million plus royalties.